GSK22939633 dose
|
Parameter1,2
|
Post-dose time point
|
---|
| |
1 hour
|
4 hours**
|
---|
150 mg
|
Ro (95% CI) (%)
|
63 (NC)
|
53 (NC)
|
300 mg
|
Ro (95% CI) (%)
|
37 (29, 54)
|
9 (0, 45)
|
600 mg
|
Ro (95% CI) (%)
|
72 (71, 75)
|
14 (13, 14)
|
900 mg
|
Ro (95% CI) (%)
|
55 (50, 58)
|
42 (0, 56)
|
1200 mg
|
Ro (95% CI) (%)
|
64 (60, 67)
|
0 (0, 1)
|
1500 mg
|
Ro (95% CI) (%)
|
74 (62, 79)
|
61 (52, 67)
|
-
1 Ro: CCR4 occupancy by GSK2239633 derived from the EC50 ratio (DR) for each dose group divided by the pre-dose EC50 and converted to an estimate of CCR4 occupancy (DR-1/DR).
-
2 95% CI: calculated from the 95% confidence interval (when available) of the modelled EC50.
- ** Data generated at 4 hours post-dose with GSK2239633 was highly variable.
- Ro: receptor occupancy; CI: confidence interval; NC: not calculated, insufficient data to generate a measure of variability.